Genetech Merger Price Looks Locked (DNA)

March 23, 2009 · Filed Under Cancer, M&A 

It wass doubtful that Genentech Inc. (NYSE: DNA) would be able to fetch more than the agreed-to buyout price of $95.00, but certain legal developments probably just took the last hopes and put them in the trash.  We figured the chance for a higher price was low.  But, as always, there are some who want more even after all parties have agreed on terms. FULL DETAILS are available at 24/7 Wall St.

JON C. OGG

Tags:

Comments

Comments are closed.

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed